Lilly’s Foundayo shows reduced diabetes, heart disease risk

INDIANAPOLIS - Pharmaceutical giant Eli Lilly and Company recently revealed findings from its ATTAIN-1 trial, revealing that its diabetes medication Foundayo significantly reduced the likelihood of developing type 2 diabetes and cardiovascular disease in overweight or obese adults with weight-related health issues. As per a press release, at 72 weeks, those taking Foundayo 17.2 mg experienced a 57% lower risk of type 2 diabetes compared to placebo, and an 18% decrease in cardiovascular disease risk.

Lower doses, namely 5.5 mg and 9 mg, also indicated reductions in type 2 diabetes risk, with 45% and 50% decreases respectively. The baseline 10-year predicted risk for type 2 diabetes among participants ranged from 16.0% to 17.3%, and the cardiovascular risk spanned from 8.5% to 8.9%. At 72 weeks, the change in risk was -9.8% for the 17.2 mg dosage compared to -1.7% for placebo, and -1.0% for cardiovascular disease risk versus 0.6% for placebo.

Foundayo, an FDA-approved once-daily pill for obesity and obesity-related conditions, contains orforglipron, a glucagon-like peptide-1 receptor agonist, which can be taken without dietary or hydration restrictions. The trial, a Phase 3, 72-week study, involved 3,127 participants across various countries and compared doses of Foundayo to placebo.